Biogen Management
Management criteria checks 2/4
Biogen's CEO is Chris Viehbacher, appointed in Nov 2022, has a tenure of 1.42 years. total yearly compensation is $30.49M, comprised of 0.5% salary and 99.5% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth ARS1.24B. The average tenure of the management team and the board of directors is 4.3 years and 4.8 years respectively.
Key information
Chris Viehbacher
Chief executive officer
US$30.5m
Total compensation
CEO salary percentage | 0.5% |
CEO tenure | 1.4yrs |
CEO ownership | 0.005% |
Management average tenure | 4.3yrs |
Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$1b |
Dec 31 2023 | n/a | n/a | US$1b |
Sep 30 2023 | n/a | n/a | US$1b |
Jun 30 2023 | n/a | n/a | US$3b |
Mar 31 2023 | n/a | n/a | US$3b |
Dec 31 2022 | US$30m | US$154k | US$3b |
Compensation vs Market: Chris's total compensation ($USD30.49M) is above average for companies of similar size in the AR market ($USD6.04M).
Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.
CEO
Chris Viehbacher (62 yo)
1.4yrs
Tenure
US$30,488,593
Compensation
Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.4yrs | US$30.49m | 0.0048% $ 1.2b | |
Executive VP & CFO | 3.7yrs | US$7.21m | 0.013% $ 3.4b | |
Head of Pharmaceutical Operations & Technology | 2.3yrs | US$4.93m | 0.0066% $ 1.7b | |
Executive VP & Chief Legal Officer | 18.3yrs | US$6.79m | 0.036% $ 9.2b | |
Executive VP & Chief Human Resources Officer | 6.8yrs | US$5.08m | 0.0094% $ 2.4b | |
Senior VP & Chief Accounting Officer | 5.4yrs | no data | 0.0043% $ 1.1b | |
Senior VP & Head of Investor Relations | 1.1yrs | no data | no data | |
Chief Communication Officer & Head of Corporate Affairs | 4.3yrs | no data | no data | |
Executive VP & Head of Corporate Development | less than a year | no data | no data | |
President & Head of North America | 6.8yrs | no data | no data | |
Head of Biotherapeutics & Medicinal Sciences | 6.8yrs | no data | no data | |
Executive VP | 4.3yrs | no data | 0.0034% $ 865.4m |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Management: BIIB's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.4yrs | US$30.49m | 0.0048% $ 1.2b | |
Independent Director | 14.1yrs | US$435.25k | 0.012% $ 3.1b | |
Independent Director | 4.8yrs | US$410.25k | 0.0029% $ 741.8m | |
Independent Chair of the Board | 14.3yrs | US$425.25k | 0.016% $ 4.1b | |
Independent Director | 14.1yrs | US$410.25k | 0.014% $ 3.5b | |
Independent Director | 2.8yrs | US$413.79k | 0.0015% $ 381.2m | |
Director | less than a year | no data | no data | |
Independent Director | 4.8yrs | US$417.75k | 0.0035% $ 901.5m | |
Director | less than a year | no data | 0.00032% $ 82.4m |
4.8yrs
Average Tenure
64yo
Average Age
Experienced Board: BIIB's board of directors are considered experienced (4.8 years average tenure).